Post-treatment ctDNA and PET/CT predict response in esophageal cancer.

A prospective study involving 123 esophageal squamous cell carcinoma patients demonstrates that post-treatment circulating tumor DNA (ctDNA) and PET/CT metrics can effectively differentiate those with pathological complete response (pCR) from non-pCR patients. The model, integrating ctDNA concentration and mean standardized uptake value (SUVmean), achieved areas under curves of 0.860 and 0.798 in discovery and validation cohorts, respectively, highlighting the potential for tailored patient management strategies based on individualized risk assessment.